ARTESUNATE

Artesunate received approval from the United States Food and Drug Administration (FDA) in 2020.

Artesunate, an antimalarial medication, is primarily used to treat malaria infections caused by the Plasmodium falciparum parasite. It is particularly effective against severe and multidrug-resistant cases of malaria.

Artesunate can be administered through intravenous (IV) for rapid action in severe cases, intramuscular (IM) as an alternative injection method, and oral as tablets for convenience in less severe cases. The choice depends on the patient's condition and instructions by the health care provider.

Common side effects of Artesunate include nausea, vomiting, headache, dizziness, and digestive discomfort. While these are generally mild and transient, more serious side effects might occur, albeit less commonly. These can include severe allergic reactions, hemolytic anemia (in individuals with G6PD deficiency), and potential liver complications.

Artesunate might cause serious adverse effects such as severe allergic reactions, hemolytic anemia (in individuals with G6PD deficiency), and rare but severe liver problems. This medication can trigger severe allergic reactions such as rash, itching, swelling, dizziness, or difficulty breathing. Stopping treatment prematurely can lead to incomplete clearance of the infection and potential relapse.

After taking Artesunate, a patient needs close monitoring for signs of adverse events such as severe allergic reactions and hemolytic anemia (in individuals with G6PD deficiency. If you experience symptoms such as rash, itching, swelling, severe dizziness, or difficulty breathing, seek medical help. Contact a healthcare provider immediately if you notice symptoms like yellowing of the eyes/skin, dark urine, persistent nausea, or abdominal pain. Finish the full prescribed course of this medication, even if symptoms improve.

Before initiating Artesunate treatment, patients should consult their healthcare provider, particularly if they are pregnant or breastfeeding, have liver or kidney problems, or are taking other medications. Any history of allergies or other relevant medical conditions should be discussed with the doctor before treatment begins. Patients should be monitored for serious adverse effects, including allergic reactions and anemia, especially in individuals with G6PD deficiency. Alcohol consumption should be avoided, and the medication should be taken strictly according to the prescribed dose and schedule. Proper storage conditions should also be followed. Any unusual or adverse reactions should be promptly reported to the healthcare provider, and the complete prescribed course should be finished. Special care may be required when treating children, elderly patients, or individuals with kidney disorders. Those traveling to malaria-endemic areas should discuss appropriate malaria prevention measures with their healthcare provider. Patients should keep emergency contact information readily available and ensure they understand the medication’s proper use and safety instructions.

KD Tripathi, Essentials of Medical Pharmacology, Antimalarial drugs, 7th edition, 2013, 829-831. Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Chemotherapy of Malaria, 12th edition, 2011, 1396. Amivas LLC, US Food and Drug Administration, [Revised on May 2020] [ Accessed on 26th August 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf